Beijing: The poll of all the claims of Donald Trump now seems to be open. While most countries in the world are struggling with the declining economy and recession due to coronavirus, China’s exports have been steadily increasing this year. No matter how many boycotts China has spoken of, China’s trade surplus with the US has reached a record 75 75.4 billion. In November, China’s total exports reached 8 268 billion.
In November, China’s exports rose sharply by 21.1 percent over the same period last year, taking its trade surplus to record levels. Strong demand from U.S. consumers has boosted China’s exports. According to data released by the Customs Department on Monday, China’s exports to the US have increased by 46 percent. The increase in exports comes at a time when the US and China are engaged in a ‘trade war’ over tariffs. China’s exports rose 11.4 percent in October. China’s imports, meanwhile, rose 5 percent to 192 192.6 billion. Imports rose 4.7 percent in October. These figures show that China’s economy has now fully recovered from the effects of the coronavirus epidemic.
China ready for Pfizer and Oxford clash
China’s Synovac Biotech has secured $515 million from a local firm to double the production capacity of its coronavirus vaccine. The companies said on Monday they expect efficacy data for their experimental shots to come out this month. Meanwhile, Synovac is also expanding tests for its COVID-19 vaccine CoronaVac. Ispar is being worked on in many other countries and where good results are coming from this vaccine. China Biopharmaceutical Limited said on Monday that 15 515 million would be invested in Synovac Life Sciences, a subsidiary of Synovac, to help develop and produce Coronavac.
China Biopharmaceuticals said in a filing with the Hong Kong Stock Exchange that the investment would pay Sino Biopharmaceuticals 15.03% interest in Synovac Life Sciences. Synovac said in a separate statement that it would be able to produce 300 million vaccine doses a year and aims to complete the construction of a second production facility by the end of 2020 to increase annual COVID-19 vaccine production capacity to 600 million doses. Synovac said that depending on market conditions and availability of financing, it may seek to expand its production capacity. Synovac has secured Coronavac supply deals with several countries, including Indonesia, Turkey, Brazil, and Chile, and is negotiating with the Philippines for potential sales.
